Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1289-1292, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (47)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, F. C. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, F. C. W.
Related Collections
Right arrow Doping in Sports Symposium
Right arrow Drug Monitoring and Toxicology
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1997;43:1289-1292.)
© 1997 American Association for Clinical Chemistry, Inc.

Doping in Sport Symposium Proceedings

Endocrine aspects of anabolic steroids

F. C. W. Wu

Department of Medicine, University of Manchester, Manchester M13 9WL, UK. Fax 0041 161 273 1389; e-mail Frederick.Wu{at}man.ac.uk


Abstract

Understanding of the mechanism of androgen action has been enhanced by advances in knowledge on the molecular basis of activation of the androgen receptor and the importance of tissue conversion of circulating testosterone to dihydrotestosterone and estradiol. New evidence supports the view that supraphysiological doses of anabolic steroids do have a definite, positive effect on muscle size and muscle strength. However, the nature of the anabolic action of androgens on muscle is currently unclear and may involve mechanisms independent of the androgen receptor. The dose–response relationships of anabolic actions vs the potentially serious risks to health of androgenic-anabolic steroids (AAS) use are still unresolved. Most of the adverse effects of AAS are reversible but some are permanent, particularly in women and children. The reported incidence of acute life-threatening events associated with AAS abuse is low, but the actual risk may be underrecognized or underreported; the exact incidence is unknown. The long-term consequences and disease risks of AAS to the sports competitor remain to be properly evaluated.


Key Words: indexing terms: androgen receptor • abused drugs • sports medicine




The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. Kvorning, M. Andersen, K. Brixen, and K. Madsen
Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1325 - E1332.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
B. L. Jones, P. J. Whiting, and L. P. Henderson
Mechanisms of anabolic androgenic steroid inhibition of mammalian {varepsilon}-subunit-containing GABAA receptors
J. Physiol., June 15, 2006; 573(3): 571 - 593.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A M Smith, K M English, C J Malkin, R D Jones, T H Jones, and K S Channer
Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina
Eur. J. Endocrinol., February 1, 2005; 152(2): 285 - 291.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
C.J. Malkin, P.J. Pugh, T.H. Jones, and K.S. Channer
Testosterone for secondary prevention in men with ischaemic heart disease?
QJM, July 1, 2003; 96(7): 521 - 529.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Basaria, J. T. Wahlstrom, and A. S. Dobs
Anabolic-Androgenic Steroid Therapy in the Treatment of Chronic Diseases
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5108 - 5117.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurophysiol.Home page
J. C. Jorge-Rivera, K. L. McIntyre, and L. P. Henderson
Anabolic Steroids Induce Region- and Subunit-Specific Rapid Modulation of GABAA Receptor-Mediated Currents in the Rat Forebrain
J Neurophysiol, June 1, 2000; 83(6): 3299 - 3309.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
B. T. Ameredes, J. F. Watchko, M. J. Daood, J. F. Rosas, M. P. Donahoe, and R. M. Rogers
Growth Hormone Improves Body Mass Recovery with Refeeding after Chronic Undernutrition-Induced Muscle Atrophy in Aging Male Rats
J. Nutr., December 1, 1999; 129(12): 2264 - 2270.
[Abstract] [Full Text]

Home page
 J. Appl. Physiol.Home page
B. T. Ameredes, J. F. Watchko, M. J. Daood, J. F. Rosas, M. P. Donahoe, and R. M. Rogers
Growth hormone restores aged diaphragm myosin composition and performance after chronic undernutrition
J Appl Physiol, October 1, 1999; 87(4): 1253 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
D. A. Cowan and A. T. Kicman
Doping in Sport: Misuse, Analytical Tests, and Legal Aspects
Clin. Chem., July 1, 1997; 43(7): 1110 - 1113.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.